arrow_back Trending Legislation
Share share

Insulin Cost Reduction Act: Ending Hidden Rebates for Medicare Patients

This bill aims to lower insulin costs for Medicare beneficiaries by prohibiting hidden price concessions that were not passed on to patients. It mandates that any negotiated discounts on insulin must directly benefit the patient at the point of sale, either at pharmacies or through mail order. This should result in lower out-of-pocket expenses for insulin.
Key points
Prohibits hidden price concessions on insulin drugs under Medicare Part D, aiming to reduce patient costs.
Insurers must pass on all negotiated insulin discounts directly to patients at the point of sale.
Changes will take effect 180 days after enactment, allowing time for implementation.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
The Insulin Cost Reduction Act
Print number: HR 5623
Sponsor: Rep. Grothman, Glenn [R-WI-6]
Process start date: 2021-10-19